{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:37:32Z","timestamp":1792892252306,"version":"4.5.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,4,30]]},"DOI":"10.2217\/fon-2017-0494","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T09:33:03Z","timestamp":1513157583000},"page":"797-807","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Pacritinib and its Use in the Treatment of Patients with Myelofibrosis who have Thrombocytopenia"],"prefix":"10.1080","volume":"14","author":[{"given":"Adolfo Enrique","family":"Diaz","sequence":"first","affiliation":[{"name":"Hematology Oncology Division, UT Health San Antonio Cancer Center, 7979 Wurzbach Road, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A","family":"Mesa","sequence":"additional","affiliation":[{"name":"Hematology Oncology Division, UT Health San Antonio Cancer Center, 7979 Wurzbach Road, San Antonio, TX 78229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8711"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.08.002"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.06.001"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.69"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.286"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.35"},{"issue":"1","key":"e_1_3_3_11_1","first-page":"208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","author":"Cross NC","year":"2011","unstructured":"Cross NC . Genetic and epigenetic complexity in myeloproliferative neoplasms. ASH Education Program Book2011(1), 208\u2013214 (2011).","journal-title":"ASH Education Program Book"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-486050"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.83"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.90"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.277"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-238956"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-575373"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328955"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3863"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0169"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24592"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-293415"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.405.405"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.406.406"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.06.002"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3099-2"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S53348"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.148"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-79"},{"key":"e_1_3_3_37_1","first-page":"75","article-title":"Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera","volume":"8","author":"Raedler LA","year":"2015","unstructured":"Raedler LA . Jakafi (ruxolitinib): first FDA-approved medication for the treatment of patients with polycythemia vera. Am. Health Drug Benefits8, 75\u201379 (2015).","journal-title":"Am. Health Drug Benefits"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200326p"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.148"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S110702"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.3905.3905"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5223"},{"issue":"2","key":"e_1_3_3_44_1","first-page":"472","article-title":"First report of the Phase-I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis","volume":"95","author":"Seymour F","year":"2010","unstructured":"Seymour F , ToB, GohA, MeadowsL, EthirajuluA, WoodA. First report of the Phase-I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis. Haematologica95(Suppl. 2), 472 (2010).","journal-title":"Haematologica"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-484832"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.6515"},{"key":"e_1_3_3_47_1","unstructured":"Verstovsek S CernohousP KomrokjiRet al. Safety overview of Phase 1\u20132 studies of pacritinib a non-myelosuppressive JAK2\/FLT3 inhibitor in patients with hematological malignancies (2013). www.ctibiopharma.com\/wp-content\/uploads\/2014\/05\/pac_eha1_june2013.pdf."},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.395.395"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30027-3"},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","unstructured":"Mascarenhas J HoffmanR TalpazMet al. Results of the Persist-2 Phase 3 study of pacritinib (PAC) versus best available therapy (BAT) including ruxolitinib (RUX) in patients (pts) with myelofibrosis (MF) and platelet counts < 100 000\/\u03bcl (2016). www.ctibiopharma.com\/wp-content\/uploads\/2016\/12\/Mascarenhas_PERSIST-2_ASH_4Dec2016-FINALf.pdf.","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5"},{"key":"e_1_3_3_51_1","unstructured":"PR Newswire\n. CTI BioPharma announces removal of full clinical hold on pacritinib (2017). www.prnewswire.com\/news-releases\/cti-biopharma-announces-removal-of-full-clinical-hold-on-pacritinib-300386115.html."},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30088-1"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7001"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.215"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1936.1936"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151126"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0403-0"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:45:06Z","timestamp":1719110706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,4,30]]}},"alternative-id":["10.2217\/fon-2017-0494"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0494","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}